Search

Displaying results 2651 - 2660 of 10000 in total
  1. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

    Synonyms: N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid, N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid
  2. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.

    Categories: Complex Mixtures
  3. Target

    General transcription and DNA repair factor IIH helicase/translocase subunit XPB

    go.drugbank.com/bio_entities/BE0012820
    TargetHumans

    Component of the general transcription and DNA repair factor IIH (TFIIH) core complex (PubMed:10024882, PubMed:17466626, PubMed:8157004, PubMed:8465201). … The structure of the TFIIH transcription complex differs from the NER-TFIIH complex; large movements by XPD/ERCC2 and XPB/ERCC3 are stabilized by XPA (PubMed:31253769, PubMed:33902107).

    Synonyms: TFIIH basal transcription factor complex 89 kDa subunit
  4. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

  5. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

  6. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]

    Synonyms: DNA (recombinant replication-deficient Gorilla gorilla gorilla adenovirus strain GC4 vector PRGN-2012 human cytomegalovirus promoter plus human papillomavirus 6/11 E2, E4, E6, E7 protein 11 epitope-containing, Replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins
  7. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  8. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

  9. Drug

    Casein

    go.drugbank.com/drugs/DB10516
    Approved

    Casein allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Products: MOXIFLOXACINA DOUBLE-E PHARMA